Filters

New Line of Cancer Antibodies

411 products

Showing 121 - 144 of 411 products
View
Western blot analysis of adult mouse brain untreated (lanes 1, 3, 5, & 7) or treated with lambda phosphatase (lanes 2, 4, 6, & 8). The blots were probed with rat monoclonal anti-EB3 (EM5091) (lanes 1 & 2), and rabbit polyclonals anti-EB3 (Ser-162) (lanes 3 & 4), anti-EB3 (Ser-176) (lanes 5 & 6), and anti-EB3 (a.a. 171-182) (lanes 7 & 8).
PhosphoSolutions Anti-EB3 (central region) Antibody
$275
Western blot analysis of adult mouse brain untreated (lanes 1, 3, 5, & 7) or treated with lambda phosphatase (lanes 2, 4, 6, & 8). The blots were probed with rat monoclonal anti-EB3 (EM5091) (lanes 1 & 2), and rabbit polyclonals anti-EB3 (Ser-162) (lanes 3 & 4), anti-EB3 (Ser-176) (lanes 5 & 6), and anti-EB3 (a.a. 171-182) (lanes 7 & 8).
PhosphoSolutions Anti-EB3 (Ser-162), Phosphospecific Antibody
$329
Western blot analysis of adult mouse brain untreated (lanes 1, 3, 5, & 7) or treated with lambda phosphatase (lanes 2, 4, 6, & 8). The blots were probed with rat monoclonal anti-EB3 (EM5091) (lanes 1 & 2), and rabbit polyclonals anti-EB3 (Ser-162) (lanes 3 & 4), anti-EB3 (Ser-176) (lanes 5 & 6), and anti-EB3 (a.a. 171-182) (lanes 7 & 8).
PhosphoSolutions Anti-EB3 (Ser-176), Phosphospecific Antibody
$329
Western blot of EB proteins in mouse brain (lanes 1-5). The blot was probed with rat monoclonals EM5041 anti-EB1 (lane 1), EM5061 anti-EB1/2/3 (lane 2), EM5081 anti-EB2 (lane 3), EM5101 anti-EB3 (lane 4), and EM5091 anti-EB3 (lane 5). Then the antibodies were detected using goat anti-Rat IgG Light Chain specific:HRP (RS3121).
PhosphoSolutions Anti-EB3 Antibody
$275
Western blot of EB proteins in mouse brain (lanes 1-5). The blot was probed with rat monoclonals EM5041 anti-EB1 (lane 1), EM5061 anti-EB1/2/3 (lane 2), EM5081 anti-EB2 (lane 3), EM5101 anti-EB3 (lane 4), and EM5091 anti-EB3 (lane 5). Then the antibodies were detected using goat anti-Rat IgG Light Chain specific:HRP (RS3121).Immunocytochemical labeling of EB3 in paraformaldehyde-fixed and NP40-permeabilized A431 cells. The cells were dual labeled with mouse monoclonal anti-α-Tubulin (TM4111) (green) and rat monoclonal anti-EB3 (EM5091) (red). The antibodies were detected using either goat anti-mouse:DyLight® 488 (MS3011) or goat anti-Rat:DyLight® 594 (RS3111).
PhosphoSolutions Anti-EB3 Antibody
$360
Western blot image of eEF2K in human A431 (lane 1), Jurkat (lane 2), and HeLa (lane 3) cells, and immunoprecipitation of eEF2K from HeLa cell lysate using anti-eEF2K (C-terminus) antibody (lanes 4 & 6). Negative control immunopreciptations with no antibody are shown in lane 5 and 7. The blots were probed with anit-eEF2K (C-terminus) (lanes 1-5) or with anti-eEF2K (N-terminal) antibody (lanes 6 & 7).Immunocytochemical labeling of eEF2K in paraformaldehyde fixed and NP-40 permeabilized A431 cells. The cells were labeled with rabbit polyclonal anti-eEF2K (EP4661). The antibody was detected using goat anti-rabbit DyLight® 594.
PhosphoSolutions Anti-eEF2K (C-terminus) Antibody
$275
Recombinant human eEF2K untreated (lanes 1 and 4) and phosphorylated with p38 kinase in vitro (lanes 2 & 5). After in vitro reaction, the eEF2K was dephosphorylated with lambda phosphatase (lanes 3 & 6). The blots were probed with rabbit polyclonal anti-eEF2K (N-terminus) (lanes 1-3) or anti-eEF2K (Ser-359) (lanes 4-6). (Images provided by the laboratory of Dr. Kevin Dalby in the Dept. of Pharmacy at the University of Texas at Austin.)
PhosphoSolutions Anti-eEF2K (Ser-359), Phosphospecific Antibody
$329
Western blot image of human Jurkat cells treated with calyculin A (100 nM) for 30 min. (lanes 1-6), then some lanes of the blot were treated with lambda phosphatase (lanes 2, 4 & 6). The blot was probed with rabbit polyclonals anti-eEF2K (C-terminus) (lanes 1 & 2), anti-eEF2K (Ser-445) phospho-specific (lanes 3 & 4), and anti-eEF2K (Ser-398) phospho-specific (lanes 5 & 6).
PhosphoSolutions Anti-eEF2K (Ser-398), Phosphospecific Antibody
$329
Western blot image of human Jurkat cells treated with calyculin A (100 nM) for 30 min. (lanes 1-6), then some lanes of the blot were treated with lambda phosphatase (lanes 2, 4 & 6). The blot was probed with rabbit polyclonals anti-eEF2K (C-terminus) (lanes 1 & 2), anti-eEF2K (Ser-445) phospho-specific (lanes 3 & 4), and anti-eEF2K (Ser-398) phospho-specific (lanes 5 & 6).
PhosphoSolutions Anti-eEF2K (Ser-445), Phosphospecific Antibody
$329
Recombinant human eEF2K untreated (lanes 1 & 4), auto-phosphorylated in the presence of Ca2+ and Calmodulin (lanes 2 & 5), and dephosphorylated with lambda phosphatase (lanes 3 & 6). The blots were probed with rabbit polyclonal anti-eEF2K (N-terminus) (lanes 1-3) or anti-eEF2K (Ser-500) (lanes 4-6). (Images provided by the laboratory of Dr. Kevin Dalby in the Dept. of Pharmacy at the University of Texas at Austin.)Western blot image of C2C12 untreated (lanes 1 & 3) or treated with calyculin A (100 nM) for 30 min. (lanes 2 & 4). The blot was probed with anti-eEF2K (N-terminus) (lanes 1 & 2) and anti-eEF2K (Ser-500) (lanes 3 & 4).
PhosphoSolutions Anti-eEF2K (Ser-500), Phosphospecific Antibody
$329
Recombinant human eEF2K untreated (lanes 1 & 4) and auto-phosphorylated in the presence of Ca2+ and Calmodulin (lanes 2 & 5). In some lanes, the eEF2K was dephosphorylated with lambda phosphatase (lanes 3 & 6). The blots were probed with rabbit polyclonal anti-eEF2K (N-terminus) (lanes 1-3) or anti-eEF2K (Thr-348) (lanes 4-6). (Images provided by the laboratory of Dr. Kevin Dalby in the Dept. of Pharmacy at the University of Texas at Austin.)
PhosphoSolutions Anti-eEF2K (Thr-348), Phosphospecific Antibody
$329
Western blot image of human A431 cells treated with Calyculin A (100 nM) for 30 min. Blot lanes were untreated (lanes 1, 3, & 5) or treated with lambda phosphatase (lanes 2, 4, & 6) then were probed with anti-EGFR (a.a. 961-972) (lanes 1 & 2), anti-EGFR (Ser-967) (lanes 3 & 4), and anti-EGFR (Ser-1142) (lanes 5 & 6).Immunocytochemical labeling in A431 cells untreated or treated with Calyculin A (50 nM) for 15 min. Cells were labeled with anti-EGFR (a.a. 961-972) or anti-EGFR (Ser-1142) antibodies. The specificity of labeling was demonstrated for each antibody by blocking the signals with their respective blocking peptides, EGFR (a.a. 961-972) (EX1875) and phospho-EGFR (Ser-1142) (EX1935).
PhosphoSolutions Anti-EGFR (N-terminal region) Antibody
$275
Western blot image of human A431 cells treated with Calyculin A (100 nM) for 30 min. Blot lanes were untreated (lanes 1, 3, & 5) or treated with lambda phosphatase (lanes 2, 4, & 6) then were probed with anti-EGFR (a.a. 961-972) (lanes 1 & 2), anti-EGFR (Ser-967) (lanes 3 & 4), and anti-EGFR (Ser-1142) (lanes 5 & 6).Immunocytochemical labeling in A431 cells untreated or treated with Calyculin A (50 nM) for 15 min. Cells were labeled with anti-EGFR (a.a. 961-972) or anti-EGFR (Ser-1142) antibodies. The specificity of labeling was demonstrated for each antibody by blocking the signals with their respective blocking peptides, EGFR (a.a. 961-972) (EX1875) and phospho-EGFR (Ser-1142) (EX1935).
PhosphoSolutions Anti-EGFR (Ser-1142), Phosphospecific Antibody
$329
Western blot image of human A431 cells treated with Calyculin A (100 nM) for 30 min. Blot lanes were untreated (lanes 1, 3, & 5) or treated with lambda phosphatase (lanes 2, 4, & 6) then were probed with anti-EGFR (a.a. 961-972) (lanes 1 & 2), anti-EGFR (Ser-967) (lanes 3 & 4), and anti-EGFR (Ser-1142) (lanes 5 & 6).Immunocytochemical labeling in A431 cells untreated or treated with Calyculin A (50 nM) for 15 min. Cells were labeled with anti-EGFR (a.a. 961-972) or anti-EGFR (Ser-967) antibodies. The specificity of labeling was demonstrated for each antibody by blocking the signals with their respective blocking peptides, EGFR (a.a. 961-972) (EX1875) and phospho-EGFR (Ser-967) (EX1915).
PhosphoSolutions Anti-EGFR (Ser-967), Phosphospecific Antibody
$329
Western blot image of human A431 cells untreated (lanes 1 & 3) or treated with EGF (100 ng/ml) for 5 min. The blot was probed with anti-EGFR (Tyr-1101) monoclonal antibody (lanes 1 & 2) or anti-EGFR (Cytoplasmic) monoclonal antibody (lanes 3 & 4).Immunocytochemical labeling in A431 cells untreated or treated with EGF (100 ng/ml) for 5 min. The cells were labeled with mouse monoclonals anti-EGFR (EM1661) and anti-EGFR (Tyr-1101) (EM1991).
PhosphoSolutions Anti-EGFR (Tyr-1101), Phosphospecific Antibody
$360
Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NM2211) and rabbit polyclonal eNOS (NP2281) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
PhosphoSolutions Anti-eNOS (C-terminal region) Antibody
$360
Western blot analysis of human umbilical vein endothelial cells treated with calyculin A (100 nM) for 30 min. (lanes 1, 3, 5 & 7) then the blots were treated with lambda phosphatase (lanes 2, 4, 6 & 8). The blots were probed with anti-endothelial nitric oxide synthase (eNOS) (C-terminal region) (lanes 1 & 2), anti-eNOS (Ser-632) (lanes 3 & 4), anti-eNOS (Ser-1177) (lanes 5 & 6) and anti-eNOS (a.a. 1172-1181) (lanes 7 & 8).
PhosphoSolutions Anti-eNOS (C-terminal region) Antibody
$275
Western blot analysis of human umbilical vein endothelial cells treated with calyculin A (100 nM) for 30 min. (lanes 1, 3, 5, & 7) then the blots were treated with lambda phosphatase (lanes 2, 4, 6, & 8). The blots were probed with anti-endothelial nitric oxide synthase (eNOS) (C-terminal region) (lanes 1 & 2), anti-eNOS (Ser-632) (lanes 3 & 4), anti-eNOS (Ser-1177) (lanes 5 & 6), or anti-eNOS (a.a. 1172-1181) (lanes 7 & 8).
PhosphoSolutions Anti-eNOS (Ser-1177), Phosphospecific Antibody
$329
Western blot analysis of human umbilical vein endothelial cells stimulated with Calyculin A and untreated (lanes 1, 3, 5) or treated (lanes 2, 4, 6) with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).
PhosphoSolutions Anti-eNOS (Ser-632), Phosphospecific Antibody
$329
Western blot analysis of human umbilical vein endothelial cells stimulated with pervanadate (1 mM) for 30 min. (lanes 1, 3, & 5) then the blot was treated with alkaline phosphatase (lanes 2, 4, & 6). The blots were probed with anti-eNOS monoclonal antibody (NM2211; lanes 1 & 2), anti-eNOS (Tyr-657) phospho-specific antibody (NP4031; lanes 3 & 4), or anti-eNOS polyclonal antibody (NP2281; lanes 5 & 6).Immunocytochemical labeling of nNOS phosphorylation in rat PC12 cells differentiated with NGF. The cells were probed with mouse monoclonal (mAb) nNOS (NM4011), and rabbit polyclonal (pAb) nNOS (C-terminal region), nNOS (Tyr-895)/eNOS (Tyr-657), and nNOS (Tyr-1326)/iNOS (Tyr-1055). The antibodies were detected using appropriate secondary antibody conjugated to DyLight® 594.
PhosphoSolutions Anti-eNOS (Tyr-657)/nNOS (Tyr-895), Phosphospecific Antibody
$329
Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NM2211) and rabbit polyclonal eNOS (NP2281) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
PhosphoSolutions Anti-eNOS Antibody
$275
Western blot of native lysates including human EpCAM extracellular region (lane 1 & 6), MCF7 breast carcinoma (lane 2 & 7), A431 skin adenocarcinoma (lane 3 & 8), NCI-H1915 lung carcinoma (lane 4 & 9), and NCI-H446 lung carcinoma (lane 5 & 10). The blot was probed with mouse monoclonal anti-EpCAM (EM0391) (lanes 1-5) and mouse monoclonal anti-EpCAM (EM0421) (lanes 6-10) at 1:1000 each.Immunocytochemical labeling of EpCAM in aldehyde fixed human NCI-H1915 lung carcinoma cells. The cells were labeled with mouse monoclonal anti-EpCAM (EM0391). The antibody was detected using goat anti-mouse Ig:DyLight® 594.
PhosphoSolutions Anti-EpCAM (Extracellular region) Antibody
$360
Western blot of native lysates including human EpCAM extracellular region (lane 1 & 6), MCF7 breast carcinoma (lane 2 & 7), A431 skin adenocarcinoma (lane 3 & 8), NCI-H1915 lung carcinoma (lane 4 & 9), and NCI-H446 lung carcinoma (lane 5 & 10). The blot was probed with mouse monoclonal anti-EpCAM (EM0391) (lanes 1-5) and mouse monoclonal anti-EpCAM (EM0421) (lanes 6-10) at 1:1000 each.Immunocytochemical labeling of EpCAM in aldehyde fixed human NCI-H1915 lung carcinoma cells. The cells were labeled with mouse monoclonal anti-EpCAM (EM0421). The antibody was detected using goat anti-mouse Ig:DyLight® 594.
PhosphoSolutions Anti-EpCAM (Extracellular region) Antibody
$360
Western blot of human MDA-MB-231 breast carcinoma (lane 1), A431 epidermoid carcinoma (lane 2), NCI-H2052 epithelioid mesothelioma (lane 3), and A549 lung carcinoma (lane 4). The blot was probed with mouse monoclonal anti-EphA2 (EM0491) at 1:1000.Immunocytochemical labeling of EphA2 in aldehyde fixed human MDA-MB-231 breast carcinoma cells. The cells were labeled with mouse monoclonal anti-EphA2 (EM0491). The antibody was detected using goat anti-mouse DyLight® 594.
PhosphoSolutions Anti-EphA2 (Extracellular region) M049 Antibody
$360

Recently Viewed